Associated Papers
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ et al.
International Journal of Molecular Sciences, 2021
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A et al.
Oncotarget, 2021
33889302 (PubMed )
Supplement: oncotarget-12-791-s001.pdf
Exome sequencing identifies somatic mutations in novel driver genes in non-small cell lung cancer.
Zhang M et al.
Aging, 2020
32629428 (PubMed )
Supplement: aging-12-103500-s002..xlsx › Sheet1
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M et al.
Cell Communication and Signaling : Ccs, 2020
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.
Lee DF et al.
Molecular Cell, 2009
Select a paper to view details